<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046731</url>
  </required_header>
  <id_info>
    <org_study_id>18-007462</org_study_id>
    <nct_id>NCT04046731</nct_id>
  </id_info>
  <brief_title>Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation</brief_title>
  <official_title>The Negative Predictive Value and Non-irritant Skin Testing Concentrations of Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers are trying to develop an allergy skin test to help predict allergic responses
      to medications commonly given to patients during surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective study to accurately determine the negative predictive value
      of skin testing with NMBAs.

      It is hypothesized that the concentrations that should be used for NMBAs are actually much
      lower than previously recommended and that the higher incidence of identifiable NMBA induced
      allergic reactions during anesthesia in the past may be due to irritation of the skin rather
      than a true allergic reaction (false positives).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-Irritant Concentrations to common NMBAs</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine the NIC to common NMBAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value of Intradermal Skin Testing to commonly used NMBAs</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine Negative Predictive Value of Intradermal Skin Testing to commonly used NMBAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max Concentration used when skin testing to NMBAs</measure>
    <time_frame>1 Year</time_frame>
    <description>Close gap on the variability of the maximal concentration used when skin testing NMBAs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study team is developing a new diagnostic skin testing procedure for patients who receive NMBAs during surgery in order to determine Negative Predictive Values and Non-Irritant Concentrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin Testing</intervention_name>
    <description>Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults &gt; or = to 18 y/o undergoing surgery

        Exclusion Criteria:

          -  Minors under the age of 18 y/o, Adults unable to consent, or those Adults with
             previous allergic reaction history during previous surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexei Gonzalez Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexei Gonzalez Estrada, M.D.</last_name>
      <phone>904-953-2451</phone>
      <email>gonzalez.alexei@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ismael Carrillo-Martin, M.D.</last_name>
      <phone>904-953-3767</phone>
      <email>Carrillo-Martin.Isamel@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alexei Gonzalez Estrada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ismael Carrillo-Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Alexei Gonzalez-Estrada, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

